These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Reduction of dispersion of repolarization and prolongation of postrepolarization refractoriness explain the antiarrhythmic effects of quinidine in a model of short QT syndrome. Milberg P; Tegelkamp R; Osada N; Schimpf R; Wolpert C; Breithardt G; Borggrefe M; Eckardt L J Cardiovasc Electrophysiol; 2007 Jun; 18(6):658-64. PubMed ID: 17521304 [TBL] [Abstract][Full Text] [Related]
8. A comparison of the long-term effects of sotalol and atenolol on QT interval and arrhythmias after myocardial infarction. Cobbe SM; Alexopoulos D; Winner SJ; McCaie CP; Cobbe PC; Johnston J Eur Heart J; 1988 Jan; 9(1):24-31. PubMed ID: 2450026 [TBL] [Abstract][Full Text] [Related]
9. Sotalol: An important new antiarrhythmic. Anderson JL; Prystowsky EN Am Heart J; 1999 Mar; 137(3):388-409. PubMed ID: 10047618 [TBL] [Abstract][Full Text] [Related]
10. Sotalol: a novel beta-blocker with class III anti-arrhythmic activity. Leibowitz D J Clin Pharmacol; 1993 Jun; 33(6):508-12. PubMed ID: 8366175 [TBL] [Abstract][Full Text] [Related]
11. Monotherapy versus combination therapy with class III antiarrhythmic agents to attenuate transmural dispersion of repolarization: a potential risk factor for torsade de pointes. Shah SA; Kluger J; White CM Pharmacotherapy; 2007 Sep; 27(9):1297-305. PubMed ID: 17723083 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacodynamics of sotalol in a pediatric population with supraventricular and ventricular tachyarrhythmia. Saul JP; Ross B; Schaffer MS; Beerman L; Melikian AP; Shi J; Williams J; Barbey JT; Jin J; Hinderling PH; Clin Pharmacol Ther; 2001 Mar; 69(3):145-57. PubMed ID: 11240979 [TBL] [Abstract][Full Text] [Related]
15. Sotalol: a new agent for the treatment of ventricular arrhythmias. Samoil D; Grubb BP; Temesy-Armos PN Am J Med Sci; 1994 Jan; 307(1):49-53. PubMed ID: 8291508 [TBL] [Abstract][Full Text] [Related]
16. Sotalol: a new class III antiarrhythmic agent. Zanetti LA Clin Pharm; 1993 Dec; 12(12):883-91. PubMed ID: 8137605 [TBL] [Abstract][Full Text] [Related]
17. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring Investigators. Mason JW N Engl J Med; 1993 Aug; 329(7):452-8. PubMed ID: 8332150 [TBL] [Abstract][Full Text] [Related]
18. [Ventricular cardiac arrhythmias. New anti-arrhythmia agents]. Scholz H Z Kardiol; 1996; 85 Suppl 6():91-6. PubMed ID: 9064988 [TBL] [Abstract][Full Text] [Related]
19. Practical considerations in the use of sotalol for ventricular tachycardia and ventricular fibrillation. Campbell RW; Furniss SS Am J Cardiol; 1993 Aug; 72(4):80A-85A. PubMed ID: 8346732 [TBL] [Abstract][Full Text] [Related]
20. Sotalol. An updated review of its pharmacological properties and therapeutic use in cardiac arrhythmias. Fitton A; Sorkin EM Drugs; 1993 Oct; 46(4):678-719. PubMed ID: 7506652 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]